Dimethylaminopropylamine (DMAPA): A Reference Entry
Prefatory Note on Classification
The term "dimethylaminopropylamine" does not refer to a dietary supplement or a naturally occurring botanical ingredient. According to all authoritative chemical, toxicological, and regulatory sources, 3-dimethylaminopropylamine (DMAPA) is a synthetic industrial diamine produced at scale by chemical manufacturers. Its safety data sheet explicitly lists food, drug, pesticide, and biocidal product use as uses advised against. No monograph from the NIH Office of Dietary Supplements, the NCCIH, the WHO, the European Medicines Agency, EFSA, the German Commission E, ESCOP, or any pharmacopeia describes DMAPA as a dietary supplement or therapeutic natural ingredient. This entry documents the compound's verified chemical identity, industrial role, toxicological profile as established in peer-reviewed and official sources, and its clinically documented significance as a contact allergen — the area in which the largest body of human evidence exists.
1. Identity
Chemical Names and Synonyms
The compound's primary chemical name is 3-dimethylaminopropylamine, and it carries CAS registry number 109-55-7. It is also known by the synonyms DMAPA, N,N-Dimethyl-1,3-propanediamine, DMPDA, 3-aminopropyldimethylamine, N,N-dimethylaminopropylamine, and 3-dimethylamino-1-propylamine, among others. Its molecular formula is C₅H₁₄N₂ and its molecular weight is 102.18 g/mol. Additional registered synonyms found in the primary literature include N,N-Dimethyl-1,3-diaminopropane, with the linear structural formula (CH₃)₂N(CH₂)₃NH₂.
Structural Features
The molecule contains both a primary amino group and a tertiary amino group. It is structurally similar to diethylaminopropylamine. The presence of two distinct nitrogen functionalities at opposite ends of a three-carbon propyl chain is the basis for DMAPA's chemical reactivity and its utility as a bifunctional building block in industrial synthesis.
Physical Form
DMAPA is a clear, colorless liquid with a typical amine odor. It is completely soluble in water, benzene, heptane, and other organic solvents. Its pH value in a 5 g/L aqueous solution is approximately 12.7, its melting point is below −50 °C, and its boiling range is 132–140 °C.
Natural Source
DMAPA has no identified botanical, animal, or naturally occurring mineral source. 3-Dimethylaminopropylamine is produced by addition of dimethylamine to acrylonitrile and subsequent hydrogenation in the presence of ammonia. More specifically, DMAPA is commonly produced commercially via the reaction between dimethylamine and acrylonitrile — a Michael reaction — to produce dimethylaminopropionitrile, and a subsequent hydrogenation step yields DMAPA. This is an entirely synthetic manufacturing pathway. DMAPA does not occur as a free compound in foods, medicinal plants, or other natural sources recognized by any official health or dietary supplement authority.
Occurrence as an Impurity in Consumer Products
Although not naturally present, DMAPA is encountered by consumers indirectly because it is used as a chemical intermediate in the manufacture of certain personal care product ingredients. Dimethylaminopropylamine is an aliphatic amine present in amphoteric surfactants such as liquid soaps and shampoos; it is present as an impurity responsible for allergy from cocamidopropylbetaine. Many products contain DMAPA unintentionally because it is an impurity found in products containing cocamidopropyl betaine (CAPB), oleamidopropyl dimethylamine, or cocamidopropyl dimethylamine.
2. Established Industrial and Commercial Uses
DMAPA is a versatile chemical intermediate used across numerous industries. Its principal role in the consumer sphere is as a precursor to cocamidopropyl betaine (CAPB). Cocamidopropyl betaine is produced in a two-step manner, beginning with the reaction of dimethylaminopropylamine (DMAPA) with fatty acids from coconut or palm kernel oil, with lauric acid or its methyl ester as the main constituent. Human studies have shown that CAPB has a low sensitizing potential if impurities including amidoamine and dimethylaminopropylamine are low and tightly controlled.
Beyond surfactant synthesis, DMAPA serves a broad range of industrial functions. It is used as an intermediate in the production of binding agents, ion-exchange materials, flocculating agents for water treatment, cosmetic agents, washing and cleaning agents (betaines), additives for petroleum and other fuels, polyurethane fibers and lubricants, dyes, agrochemicals, and agents used in the photographic and textile industries. As an epoxy resin curing agent, it has the dual functions of curing agent and accelerator. DMAPA has also been shown to inhibit corrosion in boiler water treatment, and is an intermediate for gasoline and motor oil additives.
3. Traditional and Historical Use
No traditional or historical use of 3-dimethylaminopropylamine as a medicinal, dietary, or health-promoting substance has been documented in any official monograph, ethnobotanical record, traditional medicine system, or historical pharmacopeia. As a synthetic compound with no natural source, DMAPA has no pre-industrial history of use in any cultural or therapeutic tradition. It first entered industrial use in the twentieth century as the chemical industry developed large-scale processes for the synthesis of aliphatic amines. Beginning in the 1980s, reports of allergy to CAPB surfaced in the literature, which represents the earliest clinically documented encounter of human populations with DMAPA as a reactive impurity in finished personal care products.
4. Chemistry and Mechanism of Reactivity
Bifunctional Amine Chemistry
DMAPA acts as a nucleophilic amine, participating in reactions such as reductive amination, Mannich reactions, and the synthesis of heterocyclic compounds. Its mechanism of action involves its ability to donate a lone pair of electrons from the amino group, allowing it to form covalent bonds with electrophiles. This enables the compound to facilitate the formation of complex molecular structures and the synthesis of diverse chemical compounds.
N,N-Dimethyl-1,3-propylenediamine is also a useful catalyst for Knoevenagel condensation and a useful hardening agent for epoxy resin. In the context of epoxy curing, the molecule contains both primary and tertiary amino groups, and as an epoxy resin curing agent it serves the dual functions of curing agent and accelerator.
Reactivity Profile
DMAPA neutralizes acids in exothermic reactions to form salts plus water, and may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Incompatible materials include strong acids, strong oxidizing agents, acid chlorides, carbon dioxide, bases, and copper. Hazardous decomposition products include nitrogen oxides (NOₓ), carbon monoxide, carbon dioxide, and toxic fumes.
Allergenicity Mechanism
A majority of patch testing studies have shown that clinical allergy to CAPB-containing products actually reflects allergy to contaminant DMAPA in most cases. Amidoamine, another intermediate in the formation of CAPB, may also be implicated through a proposed mechanism of conversion to DMAPA in the skin. This mechanism — enzymatic hydrolysis of the amide bond of amidoamine releasing free DMAPA — has been proposed as a reason why both amidoamine and DMAPA sensitize the same patient populations. In allergic contact dermatitis, DMAPA acts as a hapten: its primary amine group is sufficiently reactive to form covalent adducts with skin proteins, generating immunogenic neoantigens that trigger type IV (delayed-type) hypersensitivity.
5. Scientific Evidence by Area of Human Health Relevance
The entirety of the human clinical evidence for DMAPA relates to its role as a contact allergen and skin/respiratory irritant. There is no clinical evidence supporting any therapeutic, nutritional, or health-promoting use. The following summarizes what the peer-reviewed literature has established.
5.1 Allergic Contact Dermatitis: Sensitization and Prevalence
The most thoroughly studied and clinically significant aspect of DMAPA in humans is its role in allergic contact dermatitis (ACD), particularly in relation to CAPB-containing personal care products.
A foundational clinical study by Foti et al. (1995, PubMed PMID 7758328) evaluated 1,200 consecutive eczematous patients. In the past year, 1,200 consecutive eczematous patients were tested with cocamidopropylbetaine 1% aqueous. Contact allergy was evinced in 46 subjects (3.8%), while irritant reactions were observed in 15 cases (1.25%). Thirty out of 46 patients with allergic reactions were subsequently tested with substances used in the synthesis of cocamidopropylbetaine, together with a sample of cocamidopropylbetaine of greater purity. In all 30 subjects, positive reactions were obtained to 3-dimethylaminopropylamine (DMPA) 1% aqueous, while the purer grade cocamidopropylbetaine at 0.5% and 1% aqueous gave positive reactions in only 10% and 53% of cases, respectively. These results suggest that DMPA present at various levels as an impurity in the commercial product is responsible for cocamidopropylbetaine allergy.
Later work confirmed this finding at a population level. It has been discovered that all individuals who are allergic to cocamidopropyl betaine (CAPB) are sensitized to 3-dimethylaminopropylamine (DMAPA) and to amidoamine, molecules which are intermediaries in CAPB synthesis, and which persist as impurities in the material that is sold; the amounts vary, depending on the quality of the CAPB in the end product.
A large retrospective analysis of cosmetic allergens in 10,061 patients (6,621 female, 3,440 male) found that responsible allergens for cocamidopropyl betaine allergy, which also cross-react with CAPB, include dimethylaminopropylamine (DMAPA) and cocamidopropyl dimethylamine (amidoamine). CAPB was the eighth most common allergen overall, causing reactions in 6.1% and 10.3% of females and males, respectively, with cosmetic allergy.
Evidence strength: This area has the most robust evidence base — multiple prospective and retrospective studies, large patient series, and replicated patch test findings — establishing DMAPA as the primary sensitizing impurity in CAPB. Evidence quality is Level III (retrospective case series and cross-sectional studies); controlled randomized trials are not applicable to this allergen research context.
5.2 Eyelid and Facial Dermatitis
DMAPA has been specifically identified as an important but underdiagnosed cause of eyelid and periorbital ACD. A published case report and review (Knopp and Watsky, Dermatitis 2008, PMID 19134437) described the case of a 42-year-old woman with intractable eyelid dermatitis in whom patch testing revealed sensitization to 3-(dimethylamino)propylamine (DMAPA). DMAPA is an important etiology of allergic contact dermatitis of the eyelids and face but is easily missed even with expanded-series patch testing.
Allergens that are more common in eyelid ACD than in non-eyelid ACD include shellac, dimethylaminopropylamine (DMAPA), gold, carmine, and thimerosal.
A critical diagnostic implication was identified: when patch-testing for eyelid and facial dermatitis, it is crucial to test with DMAPA directly, not just with CAPB; unlike commercial-grade CAPB, the CAPB in patch test kits is ultrapure and does not contain contaminant DMAPA. This means routine CAPB patch testing will miss DMAPA-specific sensitization, requiring direct testing with DMAPA.
An American Academy of Ophthalmology (AAO) systematic review published in 2025 identified 17 eligible studies (3 prospective, 14 retrospective; 25 to 3,955 participants per study). Of 135 articles identified, 17 studies were reviewed in full text and selected for inclusion and grading; all studies were rated Level III. Multiple allergens may cause ACD. The review noted DMAPA-related allergens as part of the clinically relevant allergen landscape for eyelid dermatitis.
Evidence strength: The evidence is based on case reports, case series, and retrospective studies (Level III). No prospective randomized trial is feasible or warranted for allergen identification of this type. The consistency of findings across multiple independent clinical centers is notable.
5.3 Occupational Contact Dermatitis
Occupational exposure to DMAPA — particularly in industries using CAPB-containing products, epoxy resin systems, and personal care product manufacturing — has produced documented cases of occupational ACD. Kanerva, Estlander, and Jolanki (1996, Contact Dermatitis) documented occupational allergic contact dermatitis from 3-dimethylaminopropylamine in shampoo-exposed workers. An occupational case series found that in an electronics plant, one-component epoxy coatings containing a modified polyamine hardener were used on police radio circuit boards. The hardener was a DMAPA-epoxy adduct containing about 0.16% free DMAPA. Of 105 workers, 17 (16%) were diagnosed to have work-related dermatitis. The hands were the commonly affected region (13 out of 17 cases). The latent period of dermatitis was very short, with a mean of 21.5 days. The work-related dermatoses were closely related to the type of work and working periods.
There are indications of contact and possibly respiratory allergy in relation to occupational exposure. Less than 0.9 ppm of 3-dimethylaminopropylamine in workplace air may adversely affect respiratory function.
Evidence strength: Evidence is based on occupational case series and reports. Inhalation thresholds are derived from industrial monitoring data, not controlled clinical dose-finding studies.
5.4 Areas With No Evidence of Health Benefit
A comprehensive search of PubMed, NIH ODS, NCCIH, WHO monographs, EFSA, EMA, Cochrane, and Examine.com returns no peer-reviewed human studies, animal studies translated to human use, or any regulatory authority documentation supporting a nutritional, therapeutic, ergogenic, cognitive, immune-enhancing, or any other positive health benefit from ingesting or topically applying 3-dimethylaminopropylamine. The compound has no monograph in any dietary supplement reference. Its safety data sheets explicitly advise against food or drug use.
6. Body Systems and Health Areas Associated With DMAPA
- Integumentary system (skin): DMAPA is a documented sensitizing hapten and direct skin irritant, associated with allergic contact dermatitis, particularly of the eyelids, face, scalp, and hands. Dimethylaminopropylamine is a known skin irritant and its presence as an impurity in cocamidopropyl betaine is thought to be the cause of irritation experienced by some individuals.
- Respiratory system: Workers who were occupationally exposed to DMAPA at levels of 0.55 to 1.38 mg/m³ reported impaired respiration, which may not have been fully reversible even when DMAPA levels were decreased.
- Ocular system: Allergy to 3-(dimethylamine)propylamine (DMAPA) can cause allergic dermatitis of the face, particularly the eyelids and scalp. Irritation to ocular surface tissues from direct contact has also been noted in safety data.
- Mucous membranes: Material is extremely destructive to tissue of the mucous membranes and upper respiratory tract, eyes, and skin.
7. Dosage Forms and Exposures Reported in Sources
Because DMAPA has no documented use as a dietary supplement, there are no oral therapeutic dosage recommendations, supplement serving sizes, or pharmacological dosage schedules in any authoritative source. The following exposure-related quantities appear in the scientific literature:
- Patch testing concentration: Positive reactions in clinical patch testing were obtained to 3-dimethylaminopropylamine 1% aqueous solution. This is the diagnostic concentration used in contact allergy evaluation, not a therapeutic dose.
- Animal oral toxicity (rat): In repeated-dose rat oral toxicity studies, the no observed adverse effect level (NOAEL) was 50 mg/kg and the lowest observed adverse effect level (LOAEL) was 250 mg/kg.
- Occupational air exposure threshold: Less than 0.9 ppm of 3-dimethylaminopropylamine in workplace air may adversely affect respiratory function.
- Occupational air concentration at which respiratory symptoms were reported: Workers exposed at levels of 0.55 to 1.38 mg/m³ reported impaired respiration.
- CAPB synthesis residual: Starting materials such as DMAPA represent the largest concern for impurities in CAPB synthesis, as the synthesis of these ingredients is a clean process with little to no by-products, typically yielding products that are 98–99% pure fatty acid amidopropyl dimethylamines. The aim of refined manufacturing is to minimize residual free DMAPA in finished surfactant products.
8. Safety Considerations
Regulatory Classification and SDS-Based Hazard Profile
DMAPA is classified as a corrosive substance, capable of causing severe skin burns and eye damage. Inhalation of vapors can be harmful, and it may cause respiratory irritation. It is a skin sensitizer, meaning repeated exposure can lead to allergic reactions. It is corrosive to the skin and eye, an irritant to the respiratory tract, and a skin sensitizer. It is harmful to aquatic life and can be harmful to humans if ingested or if in contact with the skin.
Acute Toxicity (Animal Data)
DMAPA is moderately toxic by ingestion and skin contact, and is a skin and eye irritant. In a SIDS (Screening Information Data Set) screen, high-dose animals exposed for 28 days to DMAPA experienced fatalities. To the best of current knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.
Chronic Toxicity and Carcinogenicity
The National Cancer Institute (NCI) Division of Cancer Biology became aware of 3-dimethylaminopropylamine (DMAPA) as a result of a review of information from the chemical industry suggesting an increase in production or use of this substance. The chronic toxicity of DMAPA and other chemicals that share structural similarities with DMAPA is poorly understood. No human carcinogenicity data are available in the peer-reviewed literature.
Contact Allergy: Clinical Management
For individuals sensitized to DMAPA, avoidance is the only established management strategy. Skin contact with 3-(dimethylamino)propylamine is required for it to cause a rash. Discontinuation of exposure to products containing 3-(dimethylamino)propylamine should result in improvement and/or the resolution of dermatitis. Contact allergy to CAPB is now infrequent, partly because of the increasing use of new non-irritating surfactants. However, cases of patients allergic to commercial CAPB who only react to DMAPA — and not to CAPB — when they are patch tested are still being reported.
Nitrosamine Concerns in Cosmetic Context
The Cosmetic Ingredient Review (CIR) Expert Panel expressed concern over N-nitrosation reactions in ingredients containing amine groups. Fatty acid amidopropyl dimethylamines, which are synthesized from DMAPA, contain secondary amide structures relevant to this concern. The CIR Panel accordingly advised the cosmetic industry to continue minimizing DMAPA concentrations in finished products.
Environmental Profile
DMAPA is readily biodegradable (60–70%). The substance contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher. However, it is harmful to aquatic life and may be harmful to aquatic organisms due to the shift in pH it can produce.
9. Summary of Evidence Quality
The human evidence base for DMAPA is confined entirely to its toxicological and allergological profile. The strongest and most consistently replicated findings — across multiple independent clinical centers, large patient cohorts, and occupational case series — document DMAPA as the principal sensitizing impurity in CAPB-containing personal care products, as a cause of eyelid and facial ACD, and as an occupational respiratory and dermal hazard. No human clinical trials, dietary intervention studies, or supplement efficacy studies of any kind exist for DMAPA. Its categorization by some commercial sources as a "dietary supplement ingredient" is not supported by any peer-reviewed, government, or pharmacopeial source and is contradicted by its regulatory classification as a corrosive industrial chemical with uses advised against in food and drug applications.
References
Go back